The Difference is in the Data
MMS is the data-focused CRO driving pharmaceutical and biotech innovation with unparalleled regulatory expertise and technological innovation. Our experts across four continents are available to support your programs 24 hours a day with an industry-leading Sponsor satisfaction rating.
Full Service Biometrics
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
Regulatory Submissions
From the Investigational New Drug (IND) application stage through New Drug Applications (NDA), our deep expertise ensures that your drug development process is efficient, compliant, and strategically aligned with standards set by global health authorities.
Safety & Risk Management
Comprehensive pharmacovigilance, safety and risk management from Phase 1 through post approval, tailored to your specific needs.
Therapeutic Expertise
From industry-firsts to well-researched indications, MMS brings specialized knowledge in rare diseases, psychedelics, oncology and radiopharmaceuticals, central nervous system (CNS) disorders, and many others.
Functional Service Provider (FSP)
A flexible and scalable FSP model, providing the right level of oversight, scale, and governance to achieve your long- and short-term strategic goals.
What Differentiates MMS From Other CROs?
Responsive
MMS is more responsive, taking responsibility for the success of every project with consistent staff and proactive solutions that exceed the expectations of a CRO partner.
Adaptable
MMS is more adaptable, knowing your satisfaction and top outcomes are dependent on our ability to remain nimble and make smart decisions based on scientifically-sound data.
Focused
MMS is more focused, providing data-centric solutions and innovative technology and processes that help accelerate and de-risk the development and approval of your therapy.
This team never stopped working towards our deadline, and from day one, we were impressed with the efficient and smart decisions brought forth by MMS to bring this drug to market.
The choice in collaborating with MMS to meet this milestone… was simple, given their deep scientific knowledge and strategic resource models.
I cannot thank the MMS Team for the outstanding support you’re providing to ensure these are prepared for submission. I am continuously impressed with the MMS team and truly value the partnership.
AI and Technology
Sponsors can rest assured knowing that MMS will bring new levels of innovation and technology to our processes and deliverables.
in Michigan
Colleagues
Globally
Applications in the
Last 5 Years
trust
Upcoming Events
MMS Insights
perspectives
December 17th, 2024
Oncology Drug Development: Webinar Learnings on the Use of Expedited Pathways and Oncology Center of Excellence Programs
perspectives
December 11th, 2024
Why Emerging Biotech Companies are Increasingly Turning to Specialized Data CROs
news
December 4th, 2024
AI in Pharma and Innovative Leadership Were on Display at the Biennial MMS Scientific Symposium
perspectives
November 26th, 2024
Finding GRASEland: Navigating the New Regulatory Path for Grandfathered OTC Drugs
perspectives
November 21st, 2024
Essential Nonclinical Strategies for Cell and Gene Therapy (CGT) Success
news
November 19th, 2024
MMS Recognized as a Top Workplace by Detroit Free Press and USA Today Network for the Fourth Consecutive Year
perspectives
November 12th, 2024
REMS Logic Modeling: Applying FDA Guidance from November 2024 CDER Webinar
news
November 8th, 2024
MMS Named a Finalist in the 2024 Fierce CRO Awards for Leadership in Regulatory Compliance
perspectives
November 6th, 2024
How to Successfully Manage Rescue Studies and Turn Around Clinical Trials Facing Failure
perspectives
October 29th, 2024
Why Outsourcing QC of Regulatory and Medical Writing Documents is a Competitive Advantage for Large Pharma Companies
perspectives
October 22nd, 2024
Choosing the Right Clinical Trial Design: A Crucial Step in Protocol Development
webinar
October 22nd, 2024
Optimal Strategies to Protect Commercially Confidential Information (CCI) in Clinical Documents and Report Trial Results Under Revised EU-CTIS Transparency Rules
perspectives
October 15th, 2024
Putting the Action in Diversity Action Plans and the Real-Time Data Visualization Technology Needed to Ensure It Happens
news
October 15th, 2024
MMS Recognized with EcoVadis Bronze Medal for Leadership in ESG Sustainability Efforts as a Leading Clinical Research Organization (CRO)
perspectives
October 8th, 2024
Diversity Action Plan Guidance Part I: Implications for Sponsors